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Abstract
Purpose—While there is growing scientific evidence for and significant advances in the use of 
genomic technologies in medicine, there is a significant lag in the clinical adoption and 
sustainability of genomic medicine. Here we describe the findings from the National Human 
Genome Research Institute’s (NHGRI) Implementing GeNomics In pracTicE (IGNITE) Network 
in identifying key constructs, opportunities, and challenges associated with driving sustainability 
of genomic medicine in clinical practice.
Methods—Network members and affiliates were surveyed to identify key drivers associated with 
implementing and sustaining a genomic medicine program. Tallied results were used to develop 
and weigh key constructs/drivers required to support sustainability of genomic medicine programs.
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Results—The top 3 driver-stakeholder dyads were 1. Genomic training for providers, 2. 
Genomic clinical decision support (CDS) tools embedded in the Electronic Health Record (EHR), 
3. Third party reimbursement for genomic testing.
Conclusion—Priorities may differ depending on healthcare systems when comparing the current 
state of key drivers vs. projected needs for supporting genomic medicine sustainability. Thus we 
provide gap-filling guidance based on IGNITE members’ experiences. Although results are 
limited to findings from the IGNITE network, their implementation, scientific and clinical 
experience may be used as a road map by others considering implementing genomic medicine 
programs.
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Introduction
The IGNITE Network (https://ignite-genomics.org/), funded by the NHGRI, strives to 
develop and implement strategies for using genomics in routine clinical care. Beginning in 
2013, 6 research institutions and 14 community partners were funded to demonstrate the 
feasibility of genomic medicine in diverse settings. In addition, 16 affiliate institutions 
voluntarily collaborate with IGNITE to learn genomic medicine implementation techniques, 
share their experiences, and participate in network activities. IGNITE strives to identify best 
practices in genomic medicine implementation, and challenges to the successful adoption 
and sustainability of genomics programs. Utilizing the collective experiences of IGNITE and 
its investigators, we identified key functions and specific actions needed for sustainability. 
We describe the process used to prioritize the drivers as they applied to four stakeholders: 
providers, payers, patients and government agencies.
Materials and Methods
Data collection and analysis were carried out in two steps. The first step involved an open-
ended survey sent to the 6 IGNITE site principal investigators and the 6 IGNITE Working 
Group chairs (https://ignite-genomics.org/about-ignite/ and https://ignite-genomics.org/
network/working-groups/) to identify the key drivers of genomic medicine sustainability. 
Based on the 12 responses received, 7 key drivers emerged as most important (Figure 1). 
The IGNITE sustainability working group, comprised of manuscript authors, then identified 
four primary stakeholders impacted by these key drivers (Figure 1), thus creating a 28 dyad 
matrix.
The second survey was designed to collect a consolidated ranking of the top 7 key drivers 
across 4 stakeholder groups (Patients, Providers, Payers and Governmental Organizations) 
from each site. Sites were provided with the 28 dyad matrix and each site was asked to select 
what they viewed as the most important dyad for each key driver. The sites were then asked 
to rank the top 7 dyads important for genomic testing sustainability with 1 being the most 
important and 7 being the least important dyad. The survey tool was disseminated via email 
to 20 IGNITE member sites (6 IGNITE study site PIs and 14 IGNITE affiliates); principal 
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investigators (PIs) and affiliate leaders were asked to collect input from their teams and 
submit a consolidated response. The consolidated responses from each member site was then 
used for analysis. Individual investigator input into the consolidated results were not 
received or reviewed by the authors. We received 18 responses from 20 sites (90% response 
rate). In addition, we received 2 survey responses from IGNITE funded study site partners, 
for a total of 20 completed surveys. Study site respondents included 11 PIs, including 8 
physicians, all with patient care and genomic medicine experience, 1 Pharm D with 
extensive genomic research and patient care background, and 2 PhD-trained PIs with 
extensive experience in genomic research. The 14-affiliate IGNITE members are comprised 
of physicians, Pharm Ds and PhDs with extensive genomic medicine and research 
experience. The sustainability-working group tabulated the results from the 20 respondent 
sites and constructed two alternate measures of importance based on these responses. The 
first measure was the proportion of institutions that reported dyad importance (i.e., ranked 
any one dyad in the top seven of the 28 possibilities), and two, the proportion of institutions 
that reported the dyads that were ranked as a “top three” priority.
Results
An analysis of the priority-setting survey responses revealed diverse opinions on which 
drivers and stakeholders were most important for genomic medicine sustainability. Of the 28 
driver-stakeholder constructs, 21 (75%) were identified by 22 respondents in their top-7 
ranking. A further analysis of these 21 constructs revealed that Provider and Payer related 
constructs were selected 7 times each, or 33% of the time each, as being the most important 
stakeholders, while Governmental Organizations and Patients were selected 5 (24%) and 2 
times (10%), respectively (see Figure 2). It is recognized that the results from both surveys 
represent the consolidated opinion of IGNITE member sites and that results outside of the 
network might differ. The three top ranked constructs deemed most important for 
sustainability were provider education, a lack of genomic focused CDS tools and 
reimbursement. The relationship between the frequency with which dyads were identified as 
important, and the relative importance assigned to each dyad, is depicted using a bubble 
chart (Figure 2).
Discussion
The analysis of the results from the IGNITE network’s consolidated, site-level surveys, 
based on its members’ experience and input, identified that their most critical sustainability 
strategies involve Provider and Payer stakeholders; however, there is considerable diversity 
of opinion as to what specific drivers need to be targeted by such efforts. Based on the 
extensive experience of IGNITE members in genomic medicine, we believe that 
sustainability of genomics in practice requires that local implementation processes be well 
planned from the onset. Findings from the IGNITE network can assist clinical sites 
interested in adopting genomic testing by helping to identify key drivers, stakeholders and 
expectations that must be met if genomics are to be implemented in a sustainable manner. 
Our findings do not negate the fact that there are many factors required for sustainability of 
genomics in clinical practice. Rather, we identify that there will be differences in priorities 
from one institution to another. Despite the fact that all survey respondents were part of the 
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IGNITE network and the small sample size; it is not surprising there was no consensus about 
which drivers were most important to the sustainability of genomic medicine in clinical 
practice. While most respondents thought providers and payers were the most critical 
stakeholders, the drivers that were thought to be most important for each stakeholder 
differed. For providers, important barriers were lack of education and the need for genomic-
focused clinical decision support (CDS) tools; whereas for payers, the barriers were related 
to reimbursement. Strategies to overcome these barriers, and the contributions of the 
IGNITE Network to these strategies, are discussed below.
Driver: Education (Provider Education)
Lack of trust and understanding of genomic testing results, and knowledge of how to 
interpret and modify treatment, can be a significant challenge among providers. The NIH 
has supported the training of the next generation of clinician-researchers by expanding 
genomic-focused Career Development Awards (K-awards) or Institutional Training Grants 
(T32 grants). Broader dissemination can be achieved by incorporating training in genomics 
in medical school curricula and encouraging Continuing Medical Education (CME) 
programs to cover this topic.1 Educational programs addressing research advances, treatment 
guidelines, and related liability laws are ideal topics for physicians, nurses and pharmacists 
already in practice.2 Additional programs may be needed to encourage active collaboration 
among nursing, counselling, and pharmacy practitioners.3 The Consolidated Framework for 
Implementation Research (CFIR) method was used to evaluate a guideline implementation 
process for the IGNITE site to support the development of such guidelines4,5 (https://ignite-
genomics.org/spark-toolbox/clinicians/).
Driver: Infrastructure (Clinical Decision Support/EHR for Providers)
Obtaining the appropriate infrastructure has historically been cited as a priority for 
sustaining clinical pharmacogenomic testing, one example of genomic implementation.6,7 
Infrastructure must include not only EHR systems that have accessible locations for ordering 
genomic tests, but also CDS tools that reduce the time and burden of finding and interpreting 
genomic information. In particular, CDS tools need to ensure that genetic information is not 
filed in the same way as other laboratory results whose validity declines with time. NHGRI 
networks such as the Electronic Medical Records and Genomics network (eMERGE8) and 
IGNITE9 have developed and cataloged key decision support tools that can be integrated 
into EHR systems (e.g., https://ignite-genomics.org/spark/clinical-decision-support-
integration-genetic-information-ehr/).
Driver: Economic Measures (Reimbursement Strategies for Payers)
The adoption and sustainability of genomic medicine is challenged by the quantity and types 
of evidence needed for payers to justify reimbursement.8 Payers state that they will not 
reimburse for new diagnostics that do not meet their thresholds for clinical validity and 
utility.10 Payers need to develop and communicate clear criteria for quantitative and 
qualitative evidence requirements so that researchers know where best to target their efforts. 
In addition, high-quality cost-effectiveness studies of genomic-based interventions are 
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needed for payers to determine if genomic medicine constitutes high value care appropriate 
for coverage.11 Comparative effectiveness research is needed to generate the evidence of 
clinical validity and utility. Findings from previous studies in genomic medicine are often 
limited due to small cohort size, and lack of diversity in patients and practice settings 
studied. Furthermore, although the cost of genetic testing has been decreasing, the economic 
value of genomic medicine in clinical practice will also depend on its larger impact on the 
overall cost of patient care throughout the healthcare system. Thus, sustainability will 
require that genomic researchers considerably expand the scope of their studies to include 
economic outcomes and underrepresented populations. Combined with the rapid pace of 
technological advancement in the field, the evidentiary requirements of payers will require 
substantial commitments of research resources, as well as material support from impacted 
government organizations (e.g., Centers for Medicare & Medicaid Services). The IGNITE 
Toolbox has archived a variety of resources to support these future research efforts (https://
ignite-genomics.org/spark-toolbox/researchers/). As the needed evidence accumulates, 
researchers will need to work closely with other organizations to ensure the coding systems 
used to report medical, surgical, and diagnostic procedures, and which underlie 
reimbursement arrangements, are revised appropriately. The IGNITE Working Group on 
Clinical Validity and Utility and Economics is developing documentation that describes the 
process to apply for new code sets (https://ignite-genomics.org/network/working-groups/#).
Conclusion
Sustainability of a new technology is fraught with many challenges. The results of this study 
from the IGNITE network demonstrate that each key driver of genomic medicine 
sustainability has relevance across the domain of stakeholders and ultimately should be 
addressed to help improve adoption, implementation, and sustainability. In our analysis of 
the data, the authors focused on the three most important constructs (dyads) requiring 
resource allocation and focus. The survey results identified provider education/training, the 
availability of CDS tools/EHRs that properly embed genomic data, and adequate 
reimbursement by third party payers for genomic testing as the three most critical areas 
required for sustainability. It should be noted, however, that constructs not ranked in the top 
3 cannot be ignored, as findings of this study should be considered site-specific. Institutions 
considering the adoption of genomic interventions should perform their own evaluation to 
determine which drivers/stakeholder constructs are most relevant for their specific situation.
When considering construct focus, it is also important to understand the complexity and 
timelines required to address stakeholder concerns associated with each key driver. For 
example, the workforce impact driver is complex, as it is linked to how the CDS and EHR is 
designed. Provider technology fatigue is a growing problem and EHRs must incorporate 
user-defined controls for alerts and display only clinically validated “pop-ups” to prevent 
undue workflow interruption. CDS tools can facilitate effective and efficient provider 
workflow. The adoption and sustainability of genomic medicine is challenged by the 
quantity and types of clinical evidence needed for implementation.12,13 Constructs 
associated with the drivers for strong clinical evidence and research and development are 
linked, requiring significant investment in time and resources to deliver the required result. 
To help overcome research barriers and facilitate clinical research, the IGNITE network has 
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developed implementation models, tools and best practices supporting the routine 
application of genomic medicine to patient care.4,9,14 Constructs associated with regulatory 
and legal issues were not highly ranked by the respondents, and can be difficult to address 
without the help of national professional organizations establishing new standards of care 
influencing provider liability and quality standards and third party payers’ reimbursement 
for genomic testing. It should also be noted one limitation of this study is that survey 
respondents were limited to IGNITE members, although the respondents have extensive 
experience in genomic medicine. To validate a non-biased result, additional survey input 
should include representations from the two stakeholder groups not yet surveyed (patients 
and payers). Based on the study results, we suggest that sustainability of genomic medicine 
in practice requires continued and adequate funding for clinical research, continued 
education of clinicians, investments in design and development by vendors supplying 
electronic medical record systems to the healthcare community, and acceptance of genomic 
medicine clinical utility by third party payers resulting in reasonable reimbursement.
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7 key drivers of genomic sustainability across 4 primary stakeholders resulting in 28 
constructs (dyads)
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Constructs weighted by frequency) selected as being important in genomic sustainability 
(A), and frequency weighted in top three of importance (B).
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